复方苦参注射液对肺癌和肝癌细胞抑瘤作用研究

Experimental Study of Anti-tumor Effect of Compound Radix Sophorae Flavescentis Injection on Lung Cancer Cells and Hepatic Carcinoma Cells

目的通过观察复方苦参注射液对肺癌LAC、Lewis细胞,肝癌Hep、H22肿瘤细胞体内、外的抑瘤效果,探讨其在治疗恶性肿瘤中的药理作用。方法采用MTT法检测复方苦参注射液对肺癌LAC细胞的体外抑制率;以实体瘤模型观察该药对Lewis肿瘤细胞和H22肿瘤细胞的抑瘤作用;以腹水瘤模型观察其对肝癌HEP肿瘤细胞生长的影响。结果复方苦参注射液对LAC细胞生长的抑制与含药血清的浓度及作用时间呈一定的相关性;复方苦参注射液高、中、低剂量组对Lewis肺癌的抑瘤率分别为46%、32.8%和22.3%(P<0.01),对H22肿瘤细胞的抑瘤率分别为37.9%、30.6%和24.2%(P<0.01);对Hep腹水型肝癌的抑瘤率分别为34.8%、17.5%和15.6%(P<0.01),与血清对照组比较,均具有显著性差异。结论复方苦参注射液对LAC细胞体外生长具有抑制作用;对实体瘤Lewis肺癌、H22肿瘤的生长均能产生明显的抑制作用;对Hep肝腹水癌细胞的生长亦有一定的抑制作用。

Objective To discuss the pharmacological mechanism of Compound Radix Sophorae Flavescentis Injection （CRSFI） by observing its effect on lung adenoearcinoma cells （LAC）, Lewis lung cancer cells, Hep ascitic carcinoma cells and hepatic carcinoma H22 cells in vitro and in vivo. Methods MTF was used to detect the in - vitro inhibitory rate of CRSFI on LAC. The model of solid tumor was established to observe the effects on Lewis lung cancer cells and H22 cells, and ascitic tumor model was used to explore the effects on Hep cells. Results In vitro, after administration of CRSFI, the inhibitory rate of the drug was correlated with the medicated serum concentration and the action time. Compared with the blank serum control, the inhibitory rate of high - , middle - and low - dose CRSFI was 46 % , 32.8 % and 22.3 % respectively on Lewis cells（ P 〈 0.01）, 37.9%, 30.6% and 24.2% respectively on H22 cells（P〈0.01）, and 34.8%, 17.5 % andlS. 6% respectively on Hep cells （ P 〈 0.01 ）. Conclusion Compound Radix Sophorae Flavescentis Injection has inhibitory effect on the growth of LAC cells in vitro, and also has depressant effects on solid tumor cell, such as Lewislung cancer cell and H22 cells, as well as Hep hepatic ascitic carcinoma cells.